Abstract

M. Maheshwar*

ABSTRACT

Asthma is the most common life-threatening pulmonary disease that requires constant monitoring. Doxofylline is a new generation xanthine derivative that works by inhibition of phosphodiesterase activities with no cardiovascular side effects that usually seen in case of theophylline and other xanthine derivatives due to decreased affinities towards adenosine A1 and A2 receptors. Doxofylline is an anti-tussive and bronchodilator used for maintenance therapy in patients suffering with asthma and chronic obstructive pulmonary disease (COPD) and is highly metabolised by liver to an extent of 80-90%. Present work studies were carried on the formulation of sublingual tablets of Doxofylline using super disintegrant like sodium starch glycolate and croscarmellose with a view to obtain rapid disintegration when held beneath the tongue, permitting direct absorption of the active ingredient by the oral mucosa and it also avoids the fast pass metabolism and improve the bioavailability. In-vitro release studies were carried out for different formulations. FTIR studies were carried out for pure drug Doxofylline and for optimised formulation to confirm that there is no interaction between drug and different excipients used in the formulation.